or funded by the National Health Service in England. It relates to all cancer patients, both adult and paediatric, in acute inpatient, day-case, outpatient settings and delivery in the community. It covers chemotherapy treatment for all solid tumours and haematological malignancies and those in clinical trials. Provision of these data is incredibly labour intensive unless EPMA software and other databases are harnessed to provide the data.
b In addition to the mandatory national submission of this data, this is a rich source of data for local use including: (i) Understanding current service demands; (ii) Modelling potential impact of new therapies; (iii) Supporting patient access schemes; (iv) Scenario planning for service transformation.
Only when all of these steps have been addressed to the satisfaction of the multidisciplinary team should the therapy be made available for use in the clinic. This is perhaps easier for new molecules where the pharmacy team can provide a gatekeeping role and not purchase the drug until all steps have been undertaken. Following the implementation of a new therapy there should also be a periodic audit/review of local experience with aims including: (1) A means of understanding local experience with a therapy after a given time period.
(2) Assurance that therapies are being used in accordance with the National Institute for Health and Care Excellence guidance/commissioning policies, informing updates to the Innovation scorecard9
(3) Potential to link patient reported toxicity (for example, UK Oncology Nursing Society 24-hour triage rapid assessment and access toolkit10
identify trends and themes which might inform alterations to patient support (for example, proactive telephone support, changes to supportive anti-emetics). ●
References 1. Derby Hospitals NHS FT. Policy for new or amended chemotherapy regimens in cancer (clinical haematology and clinical oncology). www.derbyhospitals.nhs.uk/EasysiteWeb/ getresource.ax
d?AssetID=6272&type=full&servic etype=Attachment (accessed 20 April 2015).
2. British Oncology Pharmacy Association: Standards for Pharmacy Verification of Prescriptions for Cancer Medicines 2nd April 2013 www.bopawebsite.org/contentimages/
publications/BOPA_Standards_for_Clinical_ Pharmacy_Verification_of_cancer_medicine_ prescriptions_V2_3_FINAL_9_4_13.pdf (accessed 20 April 2015).
3. Ward C. Dose-banded and outsourced IV chemotherapy – a strategy to balance demand and capacity. Clinical Pharmacist 2013;5:29–31.
4. Williamson S, Thomson D. A report into the uptake of patient access schemes in the NHS; Clinical Pharmacist 2010; 2:268–70. www. pharmaceutical-journal.com/files/rps-pjonline/
pdf/cp201007_original_paper-268.pdf (accessed 20 April 2015).
5. Manual for Cancer Services Chemotherapy Measures Version 1.0; April 2014. www.cquins. nhs.uk/download.php?d=resources/measures/
Chemotherapy_April2014.pdf (accessed 20 April 2015).
6. NHS England. The never events list; 2013/14 update. www.england.nhs.uk/wp-content/
uploads/2013/12/nev-ev-list-1314-clar.pdf (accessed 20 April 2015).
7. National Tariff Chemotherapy Regimens List 2014-15 Version 1.0.
(accessed 20 April 2015).
9. Health and Social Care Information Centre. NICE Technology Appraisals in the NHS in England, Innovation Scorecard – to June 2014, Experimental statistics, Publication date: January 20, 2015. www.hscic.gov.uk/catalogue/
PUB16404 (accessed 20 April 2015).
10. UK Oncology Nursing Society. 24 hour triage, rapid assessment and access tool. http://ukons. org/acute-oncology-forum (Membership required).
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32